Imugene will test its reformulated therapeutic cancer vaccine, HER-Vaxx, in gastric cancer at trial sites in Asia. The Phase Ib/II trial is expected to start in mid-2016. HER-Vaxx aims to replicate or improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche). Imugene aims to gain a major pharma deal following Phase II data in the buoyant cancer immunotherapy area. A$3.0m raised in October gives it sufficient funds to undertake the Phase Ib component of the
19 Feb 2016
Anti-tumour vaccine trial to start mid-2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Anti-tumour vaccine trial to start mid-2016
Imugene Ltd (IMU:ASX) | 0 0 -4.6% | Mkt Cap: 60.0m
- Published:
19 Feb 2016 -
Author:
Dr Dennis Hulme -
Pages:
13
Imugene will test its reformulated therapeutic cancer vaccine, HER-Vaxx, in gastric cancer at trial sites in Asia. The Phase Ib/II trial is expected to start in mid-2016. HER-Vaxx aims to replicate or improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche). Imugene aims to gain a major pharma deal following Phase II data in the buoyant cancer immunotherapy area. A$3.0m raised in October gives it sufficient funds to undertake the Phase Ib component of the